期刊
MOVEMENT DISORDERS
卷 25, 期 13, 页码 2211-2218出版社
WILEY
DOI: 10.1002/mds.23254
关键词
botulinum toxin; cervical dystonia; hyperhidrosis; facial aesthetics; spasticity; overactive bladder; immunogenicity; antigenicity; neutralizing antibodies
资金
- Allergan, Inc., Irvine, CA, USA
- Allergan
- National Institutes of Health, National Institute on Disability and Rehabilitation Research, Department of Defense, and Food and Drug Administration
- Advanced Bionics
- Alexza
- Capnia
- GlaxoSmithKline
- MAP Pharmaceuticals
- Merck and Co
- OrthoMcNeil
- Neuraleve
- Nupathe
- Takeda
This meta-analysis evaluated the frequency of neutralizing antibody (nAb) conversion with onabotulinumtoxinA (BOTOX (R); Allergan) across five studied indications. The analysis was based on large, controlled or prospective, open-label trials (durations 4 months to >= 2 years). Serum samples were analyzed for nAbs using the Mouse Protection Assay. Subjects who were antibody negative at baseline and had at least one analyzable postbaseline antibody assay result were included. The 16 clinical studies included 3,006 subjects; of these, 2,240 met the inclusion criteria for this analysis. Subjects received 1-15 treatments (mean 3.8 treatments) with onabotulinumtoxinA. Total doses per treatment cycle ranged from 10 or 20 units in glabellar lines to 20-500 units in cervical dystonia. The numbers of subjects who converted from an antibody-negative status at baseline to anti-body-positive status at any post-treatment time point were: cervical dystonia 4/312 (1.28%), glabellar lines 2/718 (0.28%), over-active bladder 0/22 (0%), post-stroke spasticity 1/317 (0.32%), and primary axillary hyperhidrosis 4/871 (0.46%). Across all indications, 11/2,240 subjects (0.49%) converted from antibody negative at baseline to positive at one or more post-treatment time points, but only three subjects became clinically unresponsive to onabotulinumtoxinA at some point following a positive assay. Based on these large trials, the frequency of antibody conversion after onabotulinumtoxinA treatment is very low, and infrequently leads to loss of efficacy. (C) 2010 Movement Disorder Society
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据